AGEs, contributors to placental bed vascular changes leading to preeclampsia

References

• Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344: 109–116.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 2003;31:1341–1342.
   PubMedGoogle Scholar
• Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006;1:1293–1299.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787–790.
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597–605.
   PubMed Web of Science ®Google Scholar
• Del Turco S, Basta G. An update on advanced glycation endproducts and atherosclerosis. Biofactors 2012;38: 266–274.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003;375:581–592.
   PubMed Web of Science ®Google Scholar
• Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998–5004.
   PubMed Web of Science ®Google Scholar
• Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994;23:408–419.
   PubMed Web of Science ®Google Scholar
• Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997;272:16498–16506.
   PubMed Web of Science ®Google Scholar
• Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699–1712.
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685–691.
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370:1097–1109.
   PubMed Web of Science ®Google Scholar
• Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716–3727.
   PubMed Web of Science ®Google Scholar
• Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 2011;36:625–632.
   PubMed Web of Science ®Google Scholar
• Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 2008;283:27255–27269.
   PubMed Web of Science ®Google Scholar
• Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012;4:90–102.
   PubMedGoogle Scholar
• Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004;322:1111–1122.
   PubMed Web of Science ®Google Scholar
• Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007;220:35–46.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhong J, Yang P, Gong F, Wang CY. HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes. Int J Clin Exp Pathol 2009;3:24–38.
   PubMed Web of Science ®Google Scholar
• Haupt C, Bereza M, Kumar ST, Kieninger B, Morgado I, Hortschansky P, et al. Pattern recognition with a fibril- specific antibody fragment reveals the surface variability of natural amyloid fibrils. J Mol Biol 2011;408:529–540.
   PubMed Web of Science ®Google Scholar
• Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001;17: 436–443.
   PubMed Web of Science ®Google Scholar
• Busch M, Franke S, Rüster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010;40: 742–755.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high- affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634–646.
   PubMed Web of Science ®Google Scholar
• Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002;511:170–174.
   PubMed Web of Science ®Google Scholar
• Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007;62:427–433.
   PubMed Web of Science ®Google Scholar
• Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997;99:457–468.
   PubMed Web of Science ®Google Scholar
• Dalal M, Ferrucci L, Sun K, Beck J, Fried LP, Semba RD. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. J Gerontol A Biol Sci Med Sci 2009;64:132–137.
   PubMed Web of Science ®Google Scholar
• Yeboah FK, Alli I, Yaylayan VA, Yasuo K, Chowdhury SF, Purisima EO. Effect of limited solid-state glycation on the conformation of lysozyme by ESI-MSMS peptide mapping and molecular modeling. Bioconjug Chem 2004; 15:27–34.
   PubMed Web of Science ®Google Scholar
• Yu Y, Hanssen KF, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, et al. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. BJOG 2012; 119:1512–1520.
   PubMed Web of Science ®Google Scholar
• Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999;22:1543–1548.
   PubMed Web of Science ®Google Scholar
• Zieman S, Kass D. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail 2004;10:144–149; quiz 150–151.
   PubMedGoogle Scholar
• Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025–1031.
   PubMed Web of Science ®Google Scholar
• Obayashi H, Nakano K, Shigeta H, Yamaguchi M, Yoshimori K, Fukui M, et al. Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. Biochem Biophys Res Commun 1996;226:37–41.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003;108:1070–1077.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005;54:345–350.
   PubMed Web of Science ®Google Scholar
• Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996;39:946–951.
   PubMed Web of Science ®Google Scholar
• Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011;34:442–447.
   PubMed Web of Science ®Google Scholar
• Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146–1155.
   PubMed Web of Science ®Google Scholar
• Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008;14: 946–952.
   PubMed Web of Science ®Google Scholar
• Milne R, Brownstein S. Advanced glycation end products and diabetic retinopathy. Amino Acids 2011;44:1397–1407.
   Google Scholar
• Baumann M. Role of advanced glycation end products in hypertension and cardiovascular risk: human studies. J Am Soc Hypertens 2012;6:427–435.
   PubMed Web of Science ®Google Scholar
• de Leeuw K, Graaff R, de Vries R, Dullaart RP, Smit AJ, Kallenberg CG, Bijl M. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2007;46:1551–1556.
   PubMed Web of Science ®Google Scholar
• de Groot L, Posthumus MD, Kallenberg CG, Bijl M. Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur J Clin Invest 2010;40:835–842.
   PubMed Web of Science ®Google Scholar
• Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011;32:763–777.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354–360.
   PubMed Web of Science ®Google Scholar
• Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 2010;31:334–341.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200: 481.e1–7.
   PubMed Web of Science ®Google Scholar
• Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. Am J Pathol 2009;174:1959–1971.
   PubMed Web of Science ®Google Scholar
• Hazan AD, Smith SD, Jones RL, Whittle W, Lye SJ, Dunk CE. Vascular-leukocyte interactions: mechanisms of human decidual spiral artery remodeling in vitro. Am J Pathol 2010;177:1017–1030.
   PubMed Web of Science ®Google Scholar
• Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 2011; 204:193–201.
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785–799.
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Post MD. The placenta in pre-eclampsia and intrauterine growth restriction. J Clin Pathol 2008;61: 1254–1260.
   PubMed Web of Science ®Google Scholar
• Barton M. Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. Pflugers Arch 2010; 460:825–837.
   PubMed Web of Science ®Google Scholar
• Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002;192:1–15.
   PubMed Web of Science ®Google Scholar
• Sorci G, Riuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta 2013;1833:101–109.
   PubMed Web of Science ®Google Scholar
• Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245–313.
   PubMed Web of Science ®Google Scholar
• Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007;43:332–347.
   PubMed Web of Science ®Google Scholar
• Takac I, Schröder K, Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system?Curr Hypertens Rep 2012;14:70–78.
   PubMed Web of Science ®Google Scholar
• Thomas SR, Chen K, Keaney JF. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. J Biol Chem 2002;277:6017–6024.
   PubMed Web of Science ®Google Scholar
• Lyall F. Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia. Aust N Z J Obstet Gynaecol 2006;46:266–273.
   PubMed Web of Science ®Google Scholar
• Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810–17814.
   PubMed Web of Science ®Google Scholar
• Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM. Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int 2004;65:1664–1675.
   PubMed Web of Science ®Google Scholar
• Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008;118:183–194.
   PubMed Web of Science ®Google Scholar
• Karima M, Kantarci A, Ohira T, Hasturk H, Jones VL, Nam BH, et al. Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis. J Leukoc Biol 2005;78:862–870.
   PubMed Web of Science ®Google Scholar
• Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista EL, Yagi M, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol 2008;84:292–301.
   PubMed Web of Science ®Google Scholar
• Ayilavarapu S, Kantarci A, Fredman G, Turkoglu O, Omori K, Liu H, et al. Diabetes-induced oxidative stress is mediated by Ca2+-independent phospholipase A2 in neutrophils. J Immunol 2010;184:1507–1515.
   Google Scholar
• Sick E, Brehin S, André P, Coupin G, Landry Y, Takeda K, Gies JP. Advanced glycation end products (AGEs) activate mast cells. Br J Pharmacol 2010;161:442–455.
   PubMed Web of Science ®Google Scholar
• Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001;81:102–113.
   PubMed Web of Science ®Google Scholar
• Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep 2006;58:69–74.
   PubMedGoogle Scholar
• Hung TH, Skepper JN, Burton GJ. In vitro ischemia- reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol 2001;159:1031–1043.
   PubMed Web of Science ®Google Scholar
• Knock GA, Poston L. Bradykinin-mediated relaxation of isolated maternal resistance arteries in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1996;175:1668–1674.
   PubMed Web of Science ®Google Scholar
• Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 2006;8:1–20.
   PubMedGoogle Scholar
• Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003;59: 153–160.
   PubMed Web of Science ®Google Scholar
• Mateos-Cáceres PJ, Zamorano-León JJ, Rodríguez-Sierra P, Macaya C, López-Farré AJ. New and old mechanisms associated with hypertension in the elderly. Int J Hypertens 2012;2012:150107.
   PubMedGoogle Scholar
• Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011;31:91–97.
   PubMed Web of Science ®Google Scholar
• Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269: 9889–9897.
   PubMed Web of Science ®Google Scholar
• Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279:5059–5065.
   PubMed Web of Science ®Google Scholar
• Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685–E694.
   PubMed Web of Science ®Google Scholar
• Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004;95:233–238.
   PubMed Web of Science ®Google Scholar
• Rojas A, Delgado-López F, González I, Pérez-Castro R, Romero J, Rojas I. The receptor for advanced glycation end-products: a complex signaling scenario for a promiscuous receptor. Cell Signal 2013;25:609–614.
   PubMed Web of Science ®Google Scholar
• Stitt AW, Curtis TM. Diabetes-related adduct formation and retinopathy. J Ocul Biol Dis Infor 2011;4:10–18.
   PubMedGoogle Scholar
• Holmlund U, Wähämaa H, Bachmayer N, Bremme K, Sverremark-Ekström E, Palmblad K. The novel inflammatory cytokine high mobility group box protein 1 (HMGB1) is expressed by human term placenta. Immunology 2007; 122:430–437.
   PubMed Web of Science ®Google Scholar
• Buhimschi IA, Zhao G, Pettker CM, Bahtiyar MO, Magloire LK, Thung S, et al. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation. Am J Obstet Gynecol 2007;196:181.e1–13.
   PubMedGoogle Scholar
• Oliver EA, Buhimschi CS, Dulay AT, Baumbusch MA, Abdel-Razeq SS, Lee SY, et al. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia. J Clin Endocrinol Metab 2011; 96:689–698.
   PubMed Web of Science ®Google Scholar
• Cooke CL, Brockelsby JC, Baker PN, Davidge ST. The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Pregnancy 2003;22:173–184.
   PubMed Web of Science ®Google Scholar
• Chekir C, Nakatsuka M, Noguchi S, Konishi H, Kamada Y, Sasaki A, et al. Accumulation of advanced glycation end products in women with preeclampsia: possible involvement of placental oxidative and nitrative stress. Placenta 2006; 27:225–233.
   PubMed Web of Science ®Google Scholar
• Konishi H, Nakatsuka M, Chekir C, Noguchi S, Kamada Y, Sasaki A, Hiramatsu Y. Advanced glycation end products induce secretion of chemokines and apoptosis in human first trimester trophoblasts. Hum Reprod 2004; 19:2156–2162.
   PubMed Web of Science ®Google Scholar
• Feng C, Tao Y, Shang T, Yu M. Calprotectin, RAGE and Tᵏα in hypertensive disorders in pregnancy: expression and significance. Arch Gynecol Obstet 2011;283: 161–166.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Kim YH, Kwon JY, Park YW. Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia. J Perinat Med 2011;39: 507–513.
   PubMed Web of Science ®Google Scholar
• Hájek Z, Germanová A, Koucký M, Zima T, Kopecký P, Vítkova M, et al. Detection of feto-maternal infection/ inflammation by the soluble receptor for advanced glycation end products (sRAGE): results of a pilot study. J Perinat Med 2008;36:399–404.
   PubMed Web of Science ®Google Scholar
• Germanová A, Koucký M, Hájek Z, Parízek A, Zima T, Kalousová M. Soluble receptor for advanced glycation end products in physiological and pathological pregnancy. Clin Biochem 2010;43:442–446.
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Seeger J, Waldeyer T, Schrey S, Ebert T, Lossner U, et al. Endogenous soluble receptor for advanced glycation endproducts is increased in preeclampsia. J Hypertens 2008;26:1824–1828.
   PubMed Web of Science ®Google Scholar
• Bastek JA, Brown AG, Foreman MN, McShea MA, Anglim LM, Adamczak JE, Elovitz MA. The soluble receptor for advanced glycation end products can prospectively identify patients at greatest risk for preterm birth. J Matern Fetal Neonatal Med 2012;25:1762–1768.
   PubMed Web of Science ®Google Scholar
• Harsem NK, Braekke K, Torjussen T, Hanssen K, Staff AC. Advanced glycation end products in pregnancies complicated with diabetes mellitus or preeclampsia. Hypertens Pregnancy 2008;27:374–386.
   PubMed Web of Science ®Google Scholar
• Naruse K, Sado T, Noguchi T, Tsunemi T, Yoshida S, Akasaka J, et al. Peripheral RAGE (receptor for advanced glycation endproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response. J Reprod Immunol 2012;93:69–74.
   PubMed Web of Science ®Google Scholar
• Wang B, Koga K, Osuga Y, Hirata T, Saito A, Yoshino O, et al. High mobility group box 1 (HMGB1) levels in the placenta and in serum in preeclampsia. Am J Reprod Immunol 2011;66:143–148.
   PubMed Web of Science ®Google Scholar
• de Ranitz-Greven WL, Kaasenbrood L, Poucki WK, Hamerling J, Bos DC, Visser GH, et al. Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus. Diabetes Technol Ther 2012;14:1134–1139.
   PubMed Web of Science ®Google Scholar
• Guosheng L, Hongmei S, Chuan N, Haiying L, Xiaopeng Z, Xianqiong L. The relationship of serum AGE levels in diabetic mothers with adverse fetal outcome. J Perinatol 2009;29:483–488.
   PubMed Web of Science ®Google Scholar
• Pertyńska-Marczewska M, Głowacka E, Sobczak M, Cypryk K, Wilczyński J. Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies. Am J Reprod Immunol 2009;61:175–182.
   PubMed Web of Science ®Google Scholar
• Williams MA, Enquobahrie DA, Zimmer J, Qiu CF, Hevner K, Abetew D, et al. Maternal plasma advanced glycation end products concentrations in response to oral 50-gram glucose load in mid-pregnancy: a pilot study. Clin Lab 2012; 58:1045–1050.
   PubMed Web of Science ®Google Scholar
• Romero R, Chaiworapongsa T, Savasan ZA, Hussein Y, Dong Z, Kusanovic JP, et al. Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE. J Matern Fetal Neonatal Med 2012;25:558–567.
   PubMed Web of Science ®Google Scholar
• Costantine MM, Weiner SJ, Rouse DJ, Hirtz DG, Varner MW, Spong CY, et al. Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death. Int J Dev Neurosci 2011;29:917–922.
   PubMed Web of Science ®Google Scholar